MX2015015682A - Uso de una tiazolo-pirimidinona para el tratamiento de enfermedad inflamatoria del instentino. - Google Patents

Uso de una tiazolo-pirimidinona para el tratamiento de enfermedad inflamatoria del instentino.

Info

Publication number
MX2015015682A
MX2015015682A MX2015015682A MX2015015682A MX2015015682A MX 2015015682 A MX2015015682 A MX 2015015682A MX 2015015682 A MX2015015682 A MX 2015015682A MX 2015015682 A MX2015015682 A MX 2015015682A MX 2015015682 A MX2015015682 A MX 2015015682A
Authority
MX
Mexico
Prior art keywords
inflammatory bowel
bowel disease
treatment
thiazolo
pyrimidinone
Prior art date
Application number
MX2015015682A
Other languages
English (en)
Other versions
MX358198B (es
Inventor
Chaitanya Dutt
Chauthaiwale Vijay
Ram Gupta
Shitalkumar Zambad
Shailesh Deshpande
Jignesh Kotecha
Ramesh Gupta
Sanjay Srivastava
Laxmikant Chhipa
Jaya Abraham
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of MX2015015682A publication Critical patent/MX2015015682A/es
Publication of MX358198B publication Critical patent/MX358198B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica de baja dosis, preferentemente una composición oral que comprende una cantidad terapéuticamente efectiva de ácido [(2-hidroxi-4-oxo-6,7,8,9-tetrahidro-4H,5H-10-tia-1,4a-diaza-benz o[a]azuleno-3-carbonil)-amino}-acético (compuesto A) en el intervalo de 2.5 mg a 60 mg. La presente invención también se refiere a un método para tratar enfermedad inflamatoria del intestino en un mamífero al administrar la composición farmacéutica de baja dosis. Adicionalmente, la presente invención se refiere al uso del compuesto A para la preparación de la composición farmacéutica de baja dosis para el tratamiento de enfermedad inflamatoria del intestino en un mamífero.
MX2015015682A 2013-05-14 2014-05-12 Uso de una tiazolo-pirimidinona para el tratamiento de enfermedad inflamatoria del intestino. MX358198B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1718MU2013 2013-05-14
IN2309MU2013 2013-07-09
PCT/IB2014/000707 WO2014184631A1 (en) 2013-05-14 2014-05-12 Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease

Publications (2)

Publication Number Publication Date
MX2015015682A true MX2015015682A (es) 2016-07-20
MX358198B MX358198B (es) 2018-08-08

Family

ID=50896342

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015682A MX358198B (es) 2013-05-14 2014-05-12 Uso de una tiazolo-pirimidinona para el tratamiento de enfermedad inflamatoria del intestino.

Country Status (27)

Country Link
US (2) US9610247B2 (es)
EP (1) EP2996693B1 (es)
JP (1) JP6407974B2 (es)
KR (1) KR102239649B1 (es)
CN (1) CN105209043B (es)
AU (1) AU2014266968B2 (es)
BR (1) BR112015028581B1 (es)
CA (1) CA2912011C (es)
CY (1) CY1121280T1 (es)
DK (1) DK2996693T3 (es)
EA (1) EA030590B1 (es)
ES (1) ES2712705T3 (es)
HR (1) HRP20190315T1 (es)
HU (1) HUE042691T2 (es)
IL (1) IL242490B (es)
LT (1) LT2996693T (es)
MX (1) MX358198B (es)
MY (1) MY179215A (es)
PH (1) PH12015502560A1 (es)
PL (1) PL2996693T3 (es)
PT (1) PT2996693T (es)
RS (1) RS58423B1 (es)
SG (1) SG11201509275PA (es)
SI (1) SI2996693T1 (es)
TW (1) TWI661828B (es)
UA (1) UA117244C2 (es)
WO (1) WO2014184631A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6877196B2 (ja) * 2016-03-14 2021-05-26 参天製薬株式会社 メグルミン又はその塩からなる防腐剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962530B2 (en) * 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
TWI500623B (zh) * 2009-10-13 2015-09-21 Torrent Pharmaceuticals Ltd 新穎稠合噻唑及噁唑嘧啶酮
US8541430B2 (en) * 2009-11-27 2013-09-24 Torrent Pharmaceuticals Limited Fused thiazolo and oxazolo pyrimidinones

Also Published As

Publication number Publication date
EA201592159A1 (ru) 2016-04-29
CY1121280T1 (el) 2020-05-29
ES2712705T3 (es) 2019-05-14
PH12015502560B1 (en) 2016-02-22
KR102239649B1 (ko) 2021-04-12
TWI661828B (zh) 2019-06-11
PL2996693T3 (pl) 2019-05-31
WO2014184631A1 (en) 2014-11-20
US20170157129A1 (en) 2017-06-08
PT2996693T (pt) 2019-02-27
MY179215A (en) 2020-11-02
AU2014266968B2 (en) 2019-09-19
IL242490B (en) 2018-11-29
JP6407974B2 (ja) 2018-10-17
SI2996693T1 (sl) 2019-04-30
US20160120801A1 (en) 2016-05-05
EA030590B1 (ru) 2018-08-31
BR112015028581A2 (pt) 2017-07-25
CA2912011A1 (en) 2014-11-20
CN105209043A (zh) 2015-12-30
RS58423B1 (sr) 2019-04-30
EP2996693A1 (en) 2016-03-23
AU2014266968A1 (en) 2015-12-03
JP2016518440A (ja) 2016-06-23
SG11201509275PA (en) 2015-12-30
BR112015028581B1 (pt) 2022-05-03
DK2996693T3 (en) 2019-03-18
MX358198B (es) 2018-08-08
US9610247B2 (en) 2017-04-04
NZ714098A (en) 2020-12-18
PH12015502560A1 (en) 2016-02-22
LT2996693T (lt) 2019-03-12
EP2996693B1 (en) 2018-12-12
TW201513866A (zh) 2015-04-16
KR20160008571A (ko) 2016-01-22
CA2912011C (en) 2021-10-26
CN105209043B (zh) 2019-07-02
HRP20190315T1 (hr) 2019-04-05
UA117244C2 (uk) 2018-07-10
HUE042691T2 (hu) 2019-07-29
US10471005B2 (en) 2019-11-12

Similar Documents

Publication Publication Date Title
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201690107A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
IN2014MN00948A (es)
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
IN2014MN00987A (es)
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2013012588A (es) Inhibidores de cinasa.
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
MY176246A (en) Compositions for oral administration of zoledronic acid or related compounds for treating disease
ECSP12011703A (es) Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201400064A1 (ru) Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
MX2014002394A (es) Inhibidores de rock suaves, novedosos.
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
TW201129361A (en) Methods for treating pain
PH12015502560A1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
MX2014011843A (es) Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.

Legal Events

Date Code Title Description
FG Grant or registration